Allogene’s allogeneic CAR T data give first hint of threat to marketed autologous therapies

Phase I data to be presented by Allogene at this year’s ASCO meeting provide the first evidence that allogeneic CAR T therapies could challenge marketed autologous therapies on safety and efficacy.

On Thursday, Allogene Therapeutics Inc. (NASDAQ:ALLO) rose $11.14 (36%) to $42.12, an all-time high that gives the cancer company a market cap of $5.3 billion, after data on ALLO-501, its allogeneic CAR T against CD19, were unveiled in an abstract ahead of the American Society of Clinical Oncology (ASCO) annual meeting this month. ...